MedTrace Logo

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

NCT01063283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.

Conditions

  • Advanced Non-squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

Pemetrexed 500 mg/m\^2 intravenously over 10 minutes

DRUG

Carboplatin

Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes

DRUG

Bevacizumab 7.5 mg/kg

Bevacizumab at 7.5 mg/kg intravenously over 90 minutes

DRUG

Bevacizumab 15 mg/kg

Bevacizumab at 15 mg/kg intravenously over 90 minutes

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Michael Maitland, MD., Ph.d · The University of Chicago Medical Center

  • Michael Maitland, MD., PhD · The University of Chicago Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01063283 on ClinicalTrials.gov